Prevalence of amyloid blood clots in COVID-19 plasma

Pretorius, Etheresia ; Venter, Chantelle ; Laubscher, Gert J. ; Lourens, Petrus J. ; Steenkamp, Janami ; Kell, Douglas B. (2020)

CITATION: Pretorius, E. et al. 2020. Prevalence of amyloid blood clots in COVID-19 plasma. medRxiv, doi:10.1101/2020.07.28.20163543.

The original publication is available at


The rapid detection of COVID-19 uses genotypic testing for the presence of SARS-Cov-2 virus in nasopharyngeal swabs, but it can have a poor sensitivity. A rapid, host-based physiological test that indicated whether the individual was infected or not would be highly desirable. Coagulaopathies are a common accompaniment to COVID-19, especially micro-clots within the lungs. We show here that microclots can be detected in the native plasma of COVID-19 patient, and in particular that such clots are amyloid in nature as judged by a standard fluorogenic stain. This provides a rapid and convenient test (P<0.0001), and suggests that the early detection and prevention of such clotting could have an important role in therapy.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: